Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?

被引：0
|
作者：
Patel, Shruti R. [1 ,2 ]
Neal, Joel W.
机构：
[1] Stanford Univ, Stanford Canc Inst, Dept Med, Div Med Oncol, Palo Alto, CA USA
[2] Stanford Univ, Stanford Canc Inst, Dept Med Oncol, Palo Alto, CA 94305 USA
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2023年 / 12卷 / 07期
关键词：
Osimertinib; epidermal growth factor receptor (EGFR); non-small cell lung cancer (NSCLC); adjuvant; ADAURA;
D O I：
10.21037/tlcr-23-273
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1631 / 1635
页数：5
相关论文
共 50 条
  • [21] Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States
    Huo, Gengwei
    Song, Ying
    Liu, Wenjie
    Cao, Xuchen
    Chen, Peng
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [22] Aumolertinib as adjuvant therapy in postoperative EGFR-mutated non-small cell lung cancer
    Zhang, Q.
    He, C.
    He, T.
    Wang, Y.
    Lv, W.
    Hu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S73 - S73
  • [23] Radioimmunotherapy: a game-changer for advanced non-small cell lung cancer
    Xue, Huichan
    Chen, Yunshang
    Zhou, Yun
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [24] Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
    Calvo, Emiliano
    Lee, Jong-Seok
    Kim, Sang-We
    Moreno, Victor
    deCastro Carpeno, Javier
    Weilert, Doris
    Laus, Gianluca
    Mann, Helen
    Vishwanathan, Karthick
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (08): : 1099 - 1109
  • [25] First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
    Jeong, Byeong-Ho
    Um, Sang-Won
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)
  • [26] Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
    Soria, J. -C.
    Ohe, Y.
    Vansteenkiste, J.
    Reungwetwattana, T.
    Chewaskulyong, B.
    Lee, K. H.
    Dechaphunkul, A.
    Imamura, F.
    Nogami, N.
    Kurata, T.
    Okamoto, I.
    Zhou, C.
    Cho, B. C.
    Cheng, Y.
    Cho, E. K.
    Voon, P. J.
    Planchard, D.
    Su, W. -C.
    Gray, J. E.
    Lee, S. -M.
    Hodge, R.
    Marotti, M.
    Rukazenkov, Y.
    Ramalingam, S. S.
    Boyer, Michael
    Lee, Chee
    Hughes, Brett
    O'Byrne, Kenneth
    Briggs, Peter
    Milward, Michael
    John, Thomas
    Demedts, Ingel
    Vansteenkiste, Johan
    Bustin, Frederique
    Barrios, Carlos Henrique
    Timcheva, Constanta
    Butts, Charles
    Goss, Glenwood
    Juergens, Rosalyn
    Leighl, Natasha
    Cheng, Susanna
    Burkes, Ronald
    Zhou, Caicun
    Zhang, Helong
    Shu, Yongqian
    Cheng, Ying
    Zhou, Qing
    Li, Wei
    Feng, Guosheng
    He, Yong
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 113 - 125
  • [27] Adjuvant therapy with Osimertinib in resectable EGFR-mutated lung cancer
    Gassa, Asmae
    Ozkan, Filiz
    Alakus, Hakan
    Bruns, Christiane
    ONKOLOGE, 2021, 27 (02): : 172 - 173
  • [28] Treatment strategy of EGFR-mutated non-small cell lung cancer
    Tanaka, Fumihiro
    Yoneda, Kazue
    Takenaka, Masaru
    Kuroda, Koji
    JOURNAL OF THORACIC DISEASE, 2022, 14 (03) : 602 - 606
  • [29] How to Treat EGFR-Mutated Non-Small Cell Lung Cancer
    Belani, Neel
    Liang, Katherine
    Fradley, Michael
    Judd, Julia
    Borghaei, Hossein
    JACC: CARDIOONCOLOGY, 2023, 5 (04): : 542 - 545
  • [30] Emerging drugs for EGFR-mutated non-small cell lung cancer
    Sukrithan, Vineeth
    Deng, Lei
    Barbar, Alexander
    Cheng, Haiying
    EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (01) : 5 - 16
12345